AstraZeneca Personalized Medicine Team has 10 Projects In The Clinic - McHale
This article was originally published in The Pink Sheet Daily
Duncan McHale joined the firm in May as personalized health care medical director.
You may also be interested in...
Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested
Medicaid advisory panel members suggest states should have the same flexibility as Medicare to adopt coverage with evidence development requirements for drugs with limited supporting evidence.
The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.